Gilead Sciences, Novo Nordisk Plan NASH Collaboration
April 12 2019 - 6:40AM
Dow Jones News
By Colin Kellaher
Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NOVO-B.KO,
NVO) on Friday said they will collaborate on a clinical trial
combining compounds from their pipelines in nonalcoholic
steatohepatitis, a chronic liver condition commonly known as
NASH.
The companies said the trial will be a proof-of-concept study
combining Novo's semaglutide and Gilead's cilofexor and firsocostat
for the treatment of patients with NASH.
Gilead, a Foster City, Calif., biopharmaceutical company, and
Danish pharmaceutical company Novo said they also may collaborate
on preclinical research to advance understanding of the disease,
which often affects people with diabetes and metabolic
syndrome.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 12, 2019 06:25 ET (10:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024